On Jul. 20, 2021, Regeneron announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) had approved Regeneron’s casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19.

This marked the first time the antibody cocktail, known as REGEN-COVTM in the U.S. and Ronapreveﾙ in other countries, had received a full approval to treat COVID-19.